bioquiddity logo link to home page

Josh Kriesel, Ph.D.
CEO and Director
Dr. Kriesel is co-founder of BioQuiddity and is responsible for executing and coordinating major aspects of the financing, technical, and business development activities. He earned his Ph.D. in Chemistry from the University of California at Berkeley and previously served in a variety of management roles at a medical device company in Silicon Valley. Dr. Kriesel also serves as a non-executive director of a chemical company developing, manufacturing and selling antimicrobial additives and coatings for use in the pharmaceutical, medical and consumer healthcare industries.

Ronald Pauli, MSF
Chief Financial Officer
Mr. Pauli was CFO of Sagent Pharmaceuticals (SGNT) during their initial public offering, which raised $92 million and was one of 2011’s most successful healthcare IPOs. He also brings significant business development experience to our senior management team. Mr. Pauli was intimately involved in Sagent’s negotiations, due diligence, and documentation of more than 50 international development, supply, and marketing agreements, including a joint venture that constructed an FDA-compliant sterile injectable manufacturing facility in Chengdu, China. Previously, Mr. Pauli held senior positions at a number of biopharmaceutical companies, including NeoPharm, Inc. and Abraxis BioScience, Inc. (formerly American Pharmaceutical Partners, Inc.) Additionally, Mr. Pauli is a member of the board of directors of Horizon Pharmaceuticals (NASDAQ: HZNP), and is their audit committee chair.

Doug Cullum, MBA
Vice President of Operations
Mr. Cullum has held multiple individual contributor, management and executive assignments in quality, operations, manufacturing, and engineering. He held an executive leadership position in a food and beverage packaging design and manufacturing company as well as two contract manufacturing companies. The core competency of these two contract manufacturing companies is plastic injection molding and they have served medical and medical device, high tech, commercial/industrial, and automotive industries among others. Mr. Cullum has a BS in Plastics Engineering, an MBA, and a CSCP (Certified Supply Chain Professional) certification from APICS.

Serena Joshi, MBA
Vice President of Strategic Marketing
Ms. Joshi is responsible for strategic marketing and business development activities related to lifecycle development and product planning. She also manages various aspects of the Company’s clinical and regulatory activities. Ms. Joshi earned her MBA from the University of Manchester, and has played a crucial role in helping organizations create opportunities for market entry in emerging markets and developing nations.

Christopher Vega
Vice President Controller
Mr. Vega has substantial finance and accounting experience in the medical field. He has established BioQuiddity’s accounting, financial and purchasing controls, as well as maintains the Company’s electronic document control system. Mr. Vega has created sophisticated financial models to guide BioQuiddity in forecasting, as well as valuing and negotiating potential strategic partnerships and related transactions. In addition to his degree in accounting, Mr. Vega served for five years in the U.S. Navy as a medic where he received training in Paediatric Advanced Life Support.

Ralph McNall
Director of Engineering
Mr. McNall has worked in a management capacity in a variety of engineering roles for companies including Oratec, Smith & Nephew, FoxHollow, Peak Surgical and Medtronic. He has led numerous projects from concept to launch including an infusion pump, atherectomy catheter and several electrosurgical devices. He also brings significant knowledge of production, quality and regulatory activities of both small and large companies. Mr. McNall holds a BA in Engineering from Harvey Mudd College.

Richard Watts, Ph.D.
Program Manager
Dr. Watts has led major engineering development programs at well-known medical and diagnostic companies, including Syva, Beckman-Coulter and Affymetrix. Recently, he grew the instrument manufacturing organization at a publicly traded diagnostics company from zero to US$35 million in revenue.